G-CSF conjugates

US6831158B2 · kind B2 · utility

Assignee

• Maxygen, Inc. · US

Inventors

• Torben Lauesgaard Nissen · Summit, US
• Kim Andersen · Ridgewood, US
• Christian Hansen · Hannover, DE
• Jan Mikkelsen · Copenhagen, DK
• Hans Schambye · Copenhagen, DK

Key dates

• Filing date: Jul 10, 2002
• Grant date: Dec 14, 2004
• Expiry date: Aug 25, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/42
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.